US Global Medical Distribution Group AOD Signs North American Licensing Agreement for COVID-19 Self-Test Kits with AI The Nutrijin

[Asia Economy Reporter Lee Gwanju] AI The Nutrijin's 'COVID-19 Rapid Molecular Diagnostic Kit,' which can diagnose COVID-19 infection on-site within 30 minutes with accuracy comparable to PCR equipment, is entering the North American market.

On the 10th, the U.S. global distribution group AOD announced that it has signed an exclusive supply contract for the North American market with AI The Nutrijin for 'NINA,' a paper-chip type high-speed, high-sensitivity molecular self-diagnostic kit that diagnoses the COVID-19 virus with 98% accuracy in 30 minutes without PCR analysis equipment.

AOD has been monitoring the NINA product since last year and decided to sign the contract after determining that it is prepared with PCR-level accuracy, supply pricing, and production capacity to meet U.S. market demand.

NINA is the world's first commercially successful smart biosensor using a Paper-Microfluidic Chip method. It is a cutting-edge LOP (Lab on a Paper) self-diagnostic kit that accurately diagnoses COVID-19 patients on-site within 30 minutes with 98% sensitivity and 99% specificity. Sensitivity refers to the rate of correctly identifying COVID-19 positive patients, and specificity refers to the rate of correctly identifying disease-free individuals as negative.

AOD plans to launch the NINA project team in April and target the North American market. They are also reviewing investment plans to establish a local U.S. production plant capable of producing over 100 million units annually by receiving technology transfer from AI The Nutrijin.

AOD intends to apply for the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) as soon as clinical results from the Korean Ministry of Food and Drug Safety are available. They also plan to hold a large-scale global showcase event in the U.S. to demonstrate the world's first LAB ON A PAPER NINA diagnostic, inviting major U.S. university hospitals, medical companies, medical experts, and media to coincide with the EUA approval.

An AOD official stated, "NINA can confirm COVID-19 infection on-site within 30 minutes with 98% accuracy, enabling rapid isolation and emergency response for early infected patients, significantly reducing progression to severe cases. It will be a game-changer that revolutionizes the COVID-19 prevention system in the U.S., where hundreds of thousands of confirmed cases occur daily."

Kim Jongcheol, CEO of AI The Nutrijin, said, "We are pleased to enter the North American market by partnering with AOD, which has various pharmaceutical industry networks including CVS in the U.S. We will do our best to expedite domestic clinical trials and receive clinical trial results by May at the latest."

This content was produced with the assistance of AI translation services.